Survodutide

$165.00

Survodutide is an investigational peptide that acts as a dual agonist of the glucagon receptor (GCGR) and the GLP‑1 receptor (GLP‑1R). Developed by Boehringer Ingelheim and Zealand Pharma, it has been studied in preclinical and early clinical models to explore its effects on metabolism, including energy balance and body weight regulation. Research has focused on its potential in obesity and metabolic dysfunction-associated steatohepatitis (MASH), with ongoing studies examining how it works at the molecular and cellular level.

For Research Use Only. Not intended for human consumption, medical, diagnostic, or therapeutic purposes.

SKU: VP-SURV Category:

Frequently Bought Together

Survodutide - 10mg+Bacteriostatic Water - 30mL+Insulin Syringes - 100 CT
Price for all:   $295.00

PRODUCT FAQ

What is Survodutide?
Survodutide (BI‑456906) is a synthetic peptide that acts as a dual agonist of GLP‑1 and glucagon receptors. It is studied in laboratory research to explore metabolic regulation, glucose homeostasis, and appetite signaling pathways.
How is Survodutide different from other GLP-1 receptor compounds?
Unlike standard GLP‑1 receptor agonists, Survodutide also activates the glucagon receptor. This dual activity makes it useful for studying energy balance, metabolism, and signaling pathways in research models.
What pathways is Survodutide studied for in research?
Researchers focus on GLP‑1 and glucagon receptor signaling, insulin response, glucose control, appetite regulation, and metabolic effects on fat and energy balance.
Why is Survodutide being studied?
Survodutide is studied to better understand how dual GLP‑1/glucagon receptor activation affects metabolism, energy homeostasis, and glucose regulation, and to compare its effects to single-receptor agonists in laboratory research.
Is Survodutide a peptide?
Yes. Survodutide is a synthetic peptide designed for research studies on receptor signaling and metabolic pathways.